Antimicrobial Therapy of Experimental Group B Streptococcal Infection in Mice
AUTOR(ES)
Deveikis, A.
RESUMO
Group B beta-hemolytic streptococci (GB-BHS) frequently cause severe infection in newborns. Previous in vitro studies showed accelerated killing of GB-BHS by ampicillin plus gentamicin as compared with ampicillin alone. To extend the in vitro observations, mice were infected experimentally with GB-BHS and treated with gentamicin plus ampicillin or ampicillin alone. Untreated mice died within 10 to 48 h. Compared with treatment with ampicillin alone, ampicillin-and-gentamicin therapy resulted in improved survival when the antibiotics were given in established infection or as a single dose at the time of infection. Ampicillin and gentamicin accelerated the clearing of bacteremia as compared with treatment with ampicillin alone. In view of these findings, the therapy of GB-BHS infection in newborns and other patients should be reconsidered in that a combination of ampicillin or penicillin G plus gentamicin might be superior to the use of ampicillin or penicillin G alone.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=352081Documentos Relacionados
- Mucin model for group B type III streptococcal infection in mice.
- Experimental group B streptococcal infections in mice: hematogenous virulence and mucosal colonization.
- Interleukin-10 protects neonatal mice from lethal group B streptococcal infection.
- GM-CSF–deficient mice are susceptible to pulmonary group B streptococcal infection
- Group B streptococcal infection risk factors